{"id":"NCT05136898","sponsor":"UroGen Pharma Ltd.","briefTitle":"Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)","officialTitle":"A Phase 3b, Open-Label, Single-Arm, Multicenter Study to Assess the Feasibility of Home Instillation of UGN-102 for Treatment of Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate-Risk (IR) of Recurrence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-11-30","primaryCompletion":"2023-02-02","completion":"2023-02-02","firstPosted":"2021-11-30","resultsPosted":"2024-09-19","lastUpdate":"2024-09-19"},"enrollment":8,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bladder Cancer","Urothelial Carcinoma","Urothelial Carcinoma Bladder"],"interventions":[{"type":"DRUG","name":"UGN-102","otherNames":["UGN-102 (mitomycin) for intravesical solution"]}],"arms":[{"label":"UGN-102","type":"EXPERIMENTAL"}],"summary":"This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to instillation in a clinical setting, which might mitigate patient challenges (logistical, expense, and comfort) when receiving treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation, and TEAEs of Special Interest.","timeFrame":"Up to 3 months","effectByArm":[{"arm":"UGN-102","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":8},"commonTop":["Dysuria","Fatigue","Hypertonic bladder","Urinary tract infection","Anxiety"]}}